LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

569.57 1

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

563.94

Max

580.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	26M 364M
Pardavimai	-9.3M 790M
P/E Sektoriaus vid.	20.877 49.8
Pelno marža	46.102
Darbuotojai	1,400
EBITDA	61M 524M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+14.7% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.2B 25B
Ankstesnė atidarymo kaina	568.57
Ankstesnė uždarymo kaina	569.57

Naujienos nuotaikos

By Acuity

92%

3 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

292.345 / 309.245 Palaikymas ir pasipriešinimas

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-10 23:47; UTC

Rinkos pokalbiai

Gold Falls on Renewed Inflation Concerns -- Market Talk

2026-05-10 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026-05-10 23:38; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

2026-05-10 23:14; UTC

Rinkos pokalbiai

Australia's Political Map Continues to Be Redrawn -- Market Talk

2026-05-10 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium: Expects Deal to Close in 1Q FY27

2026-05-10 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

2026-05-10 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

2026-05-10 10:21; UTC

Uždarbis

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

2026-05-09 06:05; UTC

Uždarbis

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

2026-05-08 23:55; UTC

Uždarbis

Review & Preview: Still Going Strong -- Barrons.com

2026-05-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 20:49; UTC

Uždarbis

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026-05-08 20:25; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Net $115M

2026-05-08 19:20; UTC

Rinkos pokalbiai

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026-05-08 19:18; UTC

Uždarbis

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026-05-08 19:16; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:08; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:05; UTC

Uždarbis

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026-05-08 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026-05-08 18:51; UTC

Uždarbis

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026-05-08 18:49; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 18:41; UTC

Uždarbis

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026-05-08 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026-05-08 17:14; UTC

Uždarbis

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026-05-08 17:04; UTC

Rinkos pokalbiai

Zcash Caps Off Parabolic Week -- Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

14.7% į viršų

12 mėnesių prognozė

Vidutinis 648 USD 14.7%

Aukščiausias 738 USD

Žemiausias 516 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

292.345 / 309.245Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

3 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.